Factive launch by year-end
Executive Summary
GeneSoft will launch Factive (geminfloxacin) in late 2003 after FDA approval April 4 for mild to moderate community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis. The indication follows FDA's Anti-Infective Drugs Advisory Committee recommendation (1"The Pink Sheet" March 10, p. 11)...
You may also be interested in...
GeneSoft Factive Surveillance Program Will Track Appropriate Prescribing
GeneSoft will track Factive antibiotic prescribing patterns to determine whether labeling adequately promotes short-term use of the drug
GeneSoft Factive Label Should Discourage Prolonged Use, FDA Cmte. Says
GeneSoft's Factive (gemifloxacin) labeling should recommend against exceeding the initial five- or seven-day course of treatment for acute bacterial exacerbation of chronic bronchitis and community-acquired pneumonia, members of FDA's Anti-Infective Drugs Advisory Committee said March 4
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.